Literature DB >> 16787379

SRC inhibitors as potential therapeutic agents for human cancers.

Jose G Trevino1, Justin M Summy, Gary E Gallick.   

Abstract

Selective inhibitors of the Src family of protein tyrosine kinases have been developed as therapeutic agents for human tumors, some of which are now in various stages of clinical trial. In this review, recently described novel small molecule ATP-competitive Src inhibitors are discussed, with an emphasis on their potential use as therapeutic inhibitors for advanced-stage malignancies.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16787379     DOI： 10.2174/138955706777435724

Source DB:  PubMed          Journal:  Mini Rev Med Chem        ISSN： 1389-5575            Impact factor:   3.862


  14 in total

1.  Expression and purification of Src-family kinases for solution NMR studies.

Authors:  Andrea Piserchio; David Cowburn; Ranajeet Ghose
Journal:  Methods Mol Biol       Date:  2012

Review 2.  Extranuclear signaling by estrogen: role in breast cancer progression and metastasis.

Authors:  V Cortez; M Mann; D W Brann; R K Vadlamudi
Journal:  Minerva Ginecol       Date:  2010-12

3.  Significance of ER-Src axis in hormonal therapy resistance.

Authors:  Sreeram Vallabhaneni; Binoj C Nair; Valerie Cortez; Rambabu Challa; Dimple Chakravarty; Rajeshwar Rao Tekmal; Ratna K Vadlamudi
Journal:  Breast Cancer Res Treat       Date:  2010-12-24       Impact factor: 4.872

Review 4.  Nonreceptor tyrosine kinases in prostate cancer.

Authors:  Yu-Ming Chang; Hsing-Jien Kung; Christopher P Evans
Journal:  Neoplasia       Date:  2007-02       Impact factor: 5.715

5.  Distinct effects of saracatinib on memory CD8+ T cell differentiation.

Authors:  Shinji Takai; Helen Sabzevari; Benedetto Farsaci; Jeffrey Schlom; John W Greiner
Journal:  J Immunol       Date:  2012-03-26       Impact factor: 5.422

6.  Extranuclear functions of ER impact invasive migration and metastasis by breast cancer cells.

Authors:  Dimple Chakravarty; Sujit S Nair; Bindu Santhamma; Binoj C Nair; Long Wang; Abhik Bandyopadhyay; Joseph K Agyin; Darrell Brann; Lu-Zhe Sun; I-Tien Yeh; Francis Y Lee; Rajeshwar Rao Tekmal; Rakesh Kumar; Ratna K Vadlamudi
Journal:  Cancer Res       Date:  2010-05-11       Impact factor: 12.701

7.  Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma.

Authors:  Liz Y Han; Charles N Landen; Jose G Trevino; Jyotsnabaran Halder; Yvonne G Lin; Aparna A Kamat; Tae-Jin Kim; William M Merritt; Robert L Coleman; David M Gershenson; William C Shakespeare; Yihan Wang; Raji Sundaramoorth; Chester A Metcalf; David C Dalgarno; Tomi K Sawyer; Gary E Gallick; Anil K Sood
Journal:  Cancer Res       Date:  2006-09-01       Impact factor: 12.701

Review 8.  Src family kinases as mediators of endothelial permeability: effects on inflammation and metastasis.

Authors:  M P Kim; S I Park; S Kopetz; G E Gallick
Journal:  Cell Tissue Res       Date:  2008-09-25       Impact factor: 5.249

9.  c-Src kinase inhibition reduces arrhythmia inducibility and connexin43 dysregulation after myocardial infarction.

Authors:  Cody A Rutledge; Fu Siong Ng; Matthew S Sulkin; Ian D Greener; Artem M Sergeyenko; Hong Liu; Joanna Gemel; Eric C Beyer; Ali A Sovari; Igor R Efimov; Samuel C Dudley
Journal:  J Am Coll Cardiol       Date:  2014-01-08       Impact factor: 24.094

10.  Modulation of in situ estrogen synthesis by proline-, glutamic acid-, and leucine-rich protein-1: potential estrogen receptor autocrine signaling loop in breast cancer cells.

Authors:  Rajib Rajhans; Hareesh B Nair; Sujit S Nair; Valerie Cortez; Kijima Ikuko; Nameer B Kirma; Dujin Zhou; Alan E Holden; Darrell W Brann; Shiuan Chen; Rajeshwar Rao Tekmal; Ratna K Vadlamudi
Journal:  Mol Endocrinol       Date:  2007-12-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.